Altimmune Q2 net loss $24.8M; ALT-801 Phase 1 data expected Sept 2021

Altimmune, Inc.

2022-Q2 EPS reported -$0.99 revenue$975,139

Q2 net loss $24.8M ($0.60/shr) vs $16.8M ($0.94/shr) prior year; revenue $0.1M down from $0.7M.
Cash, equivalents & investments $217.9M; raised $18.2M net via ATM in Q2.
Recorded $8.1M impairment on construction-in-progress for terminated COVID-19 vaccine program.
ALT-801 Phase 1 12-week data readout on three dose cohorts expected September 2021.
IND for NASH on track for Q3 2021; obesity IND planned Q4 2021; Phase 2 trials targeted early 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.